Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. (TNGX) is a clinical-stage biotechnology company pioneering precision oncology solutions through innovative target discovery and therapeutic development. This page provides authorized updates on their research programs, clinical trials, and strategic initiatives in cancer treatment innovation.
Investors and researchers will find verified information about TNGX's pipeline progress, including PRMT5 inhibitor developments for CNS/non-CNS cancers and discontinued programs like TNG348. All content undergoes strict verification to ensure accuracy in reporting scientific milestones and regulatory updates.
Key coverage areas include clinical trial phases, research collaborations, peer-reviewed study publications, and corporate developments. The resource is particularly valuable for tracking therapies addressing tumor suppressor gene restoration and immune evasion mechanisms.
Bookmark this page for real-time updates on Tango Therapeutics' work in CRISPR-enabled drug discovery and their mission to transform cancer treatment paradigms through precision medicine approaches.
Tango Therapeutics reported its Q2 2022 financial results, holding $416.4 million in cash. The company is advancing TNG908, an MTA-cooperative PRMT5 inhibitor, in a Phase 1/2 trial for treating MTAP-deleted solid tumors, having received Orphan Drug Designation from the FDA for malignant peripheral nerve sheath tumors. Collaboration revenue decreased to $5.8 million, while research and development expenses rose to $23.7 million. The net loss for Q2 2022 increased to $24.9 million, or $0.28 per share, compared to a loss of $4.5 million, or $0.09 per share, in Q2 2021.
Tango Therapeutics, Inc. (NASDAQ: TNGX) announced that its CEO, Barbara Weber, M.D., will participate in a virtual panel on synthetic lethality in cancer therapeutics at the 13th Annual Wedbush PacGrow Healthcare Conference on August 9 at 12:00 PM ET. The event will be accessible via a live webcast on the company's website and will remain available for replay for 30 days after the presentation. Tango is focused on advancing precision cancer therapies through innovative drug targets and leveraging synthetic lethality.
Tango Therapeutics (TNGX) announced its inclusion in the Russell 2000, Russell 3000, and Russell Microcap Indexes, effective June 24, 2022. This addition reflects increasing investor interest as the company progresses its lead asset, TNG908, into clinical trials and expands its pipeline with new candidates. According to CEO Barbara Weber, this visibility could attract new investors, enhancing the company's market position and potential growth opportunities.
Tango Therapeutics, a biotechnology firm focused on precision cancer medicines, will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 11:20 AM PT in Rancho Palos Verdes, CA. Investors can access a live webcast on the company's website under the 'Events & Presentations' section, with a replay available for 30 days afterward. Tango applies the principle of synthetic lethality to explore cancer therapies, targeting critical areas, including tumor suppressor gene loss.
Tango Therapeutics (TNGX) announced significant advancements in cancer treatments, including the start of a Phase 1/2 trial for TNG908, a PRMT5 inhibitor, now open for enrollment targeting MTAP-deleted tumors. The company also declared TNG462 and TNG260 as development candidates for similar applications. With a robust cash position of $450 million, Tango aims to progress its pipeline into late 2024. Financially, Tango reported a net loss of $25.2 million for Q1 2022, with research and development expenses rising to $24.3 million compared to $15 million a year prior.
Tango Therapeutics (NASDAQ: TNGX) announced its management team will participate in a fireside chat at Guggenheim Synthetic Lethality Day 2022 on May 16 at 10:00 AM ET. The event will be accessible via a live webcast found on the company's website under the 'Events & Presentations' section. Additionally, a replay will be available for 30 days post-event. The company focuses on developing precision cancer medicines by leveraging synthetic lethality, targeting tumor suppressor gene loss, and enhancing cancer treatments.
Tango Therapeutics (TNGX) announced significant developments, including the Fast Track Designation for its lead candidate, TNG908, an inhibitor targeting MTAP-deleted cancers. The company plans to start a Phase 1/2 clinical trial in Q2 2022, with preliminary data expected in H1 2023. Tango also reported financial results for 2021, revealing a net loss of $58.2 million and a revenue of $37 million. A strong cash position of $485 million is anticipated to support operations through the second half of 2024.
Tango Therapeutics (NASDAQ: TNGX) announced three abstracts selected for presentation at the AACR 2022 Annual Meeting, highlighting innovative cancer therapies. The presentations will cover:
- TNG908: an MTAP-null selective PRMT5 inhibitor showing tumor regressions in various cancer models.
- USP1 inhibitor: exploring synthetic lethality in BRCA1-mutant cancer via PCNA ubiquitination.
- UMIBB: introducing a Bayesian method enhancing CRISPR-Cas9 screen analysis.
These advancements aim to strengthen precision oncology and enrich Tango's therapeutic pipeline.
Tango Therapeutics, Inc. (NASDAQ: TNGX) announced the presentation of an e-Poster at the 2022 ESMO Targeted Anticancer Therapies Congress, scheduled for March 7-8, 2022. The poster titled 'Evidence for synergy between TNG908, an MTAP-null selective PRMT5 inhibitor, and sotorasib in an MTAP-null/KRASG12C xenograft model' will be presented on March 4 at 12:00 CET. Tango focuses on developing precision cancer medicines based on synthetic lethality, targeting crucial cancer pathways.
Tango Therapeutics (NASDAQ: TNGX) has announced participation in two virtual investor conferences in February 2022. The Guggenheim 2022 Oncology Conference is scheduled for February 9 at 9:00 AM ET, followed by the 11th Annual SVB Leerink Global Healthcare Conference on February 16 at 1:00 PM ET. Live webcasts of these events will be available on the company's website, with replays accessible for 30 days post-event. Tango specializes in precision cancer medicines, employing innovative approaches to target cancer effectively.